Bifidobacterium affects antitumor efficacy of oncolytic adenovirus in a mouse model of melanoma.

Autor:	Tripodi L; CEINGE Biotecnologie Avanzate Franco Salvatore s.c.a.r.l, Napoli, Italy.; Dipartimento di Medicina Molecolare e Biotecnologie Mediche, Università degli Studi di Napoli Federico II, Napoli, Italy., Feola S; Drug Research Program (DRP), ImmunoViroTherapy Lab (IVT), Division of Pharmaceutical Biosciences, Faculty of Pharmacy, University of Helsinki, Viikinkaari 5E, 00790 Helsinki, Finland., Granata I; Institute for High-Performance Computing and Networking National Research Council Branch of Naples, 509066 Naples, Naples, Italy., Whalley T; School of Biosciences, Cardiff University, Cardiff CF10 3AX, Wales, UK., Passariello M; CEINGE Biotecnologie Avanzate Franco Salvatore s.c.a.r.l, Napoli, Italy.; Dipartimento di Medicina Molecolare e Biotecnologie Mediche, Università degli Studi di Napoli Federico II, Napoli, Italy., Capasso C; Drug Research Program (DRP), ImmunoViroTherapy Lab (IVT), Division of Pharmaceutical Biosciences, Faculty of Pharmacy, University of Helsinki, Viikinkaari 5E, 00790 Helsinki, Finland., Coluccino L; CEINGE Biotecnologie Avanzate Franco Salvatore s.c.a.r.l, Napoli, Italy.; Dipartimento di Medicina Molecolare e Biotecnologie Mediche, Università degli Studi di Napoli Federico II, Napoli, Italy., Vitale M; CEINGE Biotecnologie Avanzate Franco Salvatore s.c.a.r.l, Napoli, Italy., Scalia G; CEINGE Biotecnologie Avanzate Franco Salvatore s.c.a.r.l, Napoli, Italy., Gentile L; CEINGE Biotecnologie Avanzate Franco Salvatore s.c.a.r.l, Napoli, Italy., De Lorenzo C; CEINGE Biotecnologie Avanzate Franco Salvatore s.c.a.r.l, Napoli, Italy.; Dipartimento di Medicina Molecolare e Biotecnologie Mediche, Università degli Studi di Napoli Federico II, Napoli, Italy., Guarracino MR; University of Cassino and Southern Lazio Department of Economics and Law, 154984 Cassino, Frosinone, Italy., Castaldo G; CEINGE Biotecnologie Avanzate Franco Salvatore s.c.a.r.l, Napoli, Italy.; Dipartimento di Medicina Molecolare e Biotecnologie Mediche, Università degli Studi di Napoli Federico II, Napoli, Italy., D'Argenio V; CEINGE Biotecnologie Avanzate Franco Salvatore s.c.a.r.l, Napoli, Italy.; Department of Human Sciences and Quality of Life Promotion, San Raffaele Open University, Rome, Italy., Szomolay B; Division of Infection and Immunity and Systems Immunity Research Institute, Cardiff University School of Medicine, Cardiff CF14 4XN, Wales, UK., Cerullo V; Dipartimento di Medicina Molecolare e Biotecnologie Mediche, Università degli Studi di Napoli Federico II, Napoli, Italy.; Drug Research Program (DRP), ImmunoViroTherapy Lab (IVT), Division of Pharmaceutical Biosciences, Faculty of Pharmacy, University of Helsinki, Viikinkaari 5E, 00790 Helsinki, Finland., Pastore L; CEINGE Biotecnologie Avanzate Franco Salvatore s.c.a.r.l, Napoli, Italy.; Dipartimento di Medicina Molecolare e Biotecnologie Mediche, Università degli Studi di Napoli Federico II, Napoli, Italy.
Jazyk:	angličtina
Zdroj:	IScience [iScience] 2023 Aug 19; Vol. 26 (10), pp. 107668. Date of Electronic Publication: 2023 Aug 19 (Print Publication: 2023).
DOI:	10.1016/j.isci.2023.107668
Abstrakt:	Gut microbiota plays a key role in modulating responses to cancer immunotherapy in melanoma patients. Oncolytic viruses (OVs) represent emerging tools in cancer therapy, inducing a potent immunogenic cancer cell death (ICD) and recruiting immune cells in tumors, poorly infiltrated by T cells. We investigated whether the antitumoral activity of oncolytic adenovirus Ad5D24-CpG (Ad-CpG) was gut microbiota-mediated in a syngeneic mouse model of melanoma and observed that ICD was weakened by vancomycin-mediated perturbation of gut microbiota. Ad-CpG efficacy was increased by oral supplementation with Bifidobacterium, reducing melanoma progression and tumor-infiltrating regulatory T cells. Fecal microbiota was enriched in bacterial species belonging to the Firmicutes phylum in mice treated with both Bifidobacterium and Ad-CpG; furthermore, our data suggest that molecular mimicry between melanoma and Bifidobacterium-derived epitopes may favor activation of cross-reactive T cells and constitutes one of the mechanisms by which gut microbiota modulates OVs response. Competing Interests: Vincenzo Cerullo is founder and shareholder at VALO therapeutics. (© 2023 The Authors.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu